Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan
- PMID: 35427533
- PMCID: PMC11428195
- DOI: 10.1016/S2213-2600(21)00555-5
Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan
Abstract
The traditional view of chronic obstructive pulmonary disease (COPD) as a self-inflicted disease caused by tobacco smoking in genetically susceptible individuals has been challenged by recent research findings. COPD can instead be understood as the potential end result of the accumulation of gene-environment interactions encountered by an individual over the life course. Integration of a time axis in pathogenic models of COPD is necessary because the biological responses to and clinical consequences of different exposures might vary according to both the age of an individual at which a given gene-environment interaction occurs and the cumulative history of previous gene-environment interactions. Future research should aim to understand the effects of dynamic interactions between genes (G) and the environment (E) by integrating information from basic omics (eg, genomics, epigenomics, proteomics) and clinical omics (eg, phenomics, physiomics, radiomics) with exposures (the exposome) over time (T)-an approach that we refer to as GETomics. In the context of this approach, we argue that COPD should be viewed not as a single disease, but as a clinical syndrome characterised by a recognisable pattern of chronic symptoms and structural or functional impairments due to gene-environment interactions across the lifespan that influence normal lung development and ageing.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests AA has received research funds and honoraria as a speaker and consultant from AstraZeneca, GlaxoSmithKline, Chiesi, and Menarini for initiatives related to chronic obstructive pulmonary disease (COPD), outside of the submitted work. EM has received advisory board reimbursements and fees as a speaker from AstraZeneca, Chiesi, Novartis, and Sanofi, outside of the submitted work. DLD has received research funds from the National Institutes of Health, Alpha-1 Foundation, and Bayer, and honoraria from Novartis. RB-K has received honoraria as a speaker from AstraZeneca, GlaxoSmithKline, Menarini, and Novartis. RF has received research funds from AstraZeneca, GlaxoSmithKline, and Menarini, honoraria as a speaker from Chiesi, and consultancy fees from GlaxoSmithKline for COPD-related initiatives outside of the submitted work.
Figures
Comment in
-
GETting to know the many causes and faces of COPD.Lancet Respir Med. 2022 May;10(5):426-428. doi: 10.1016/S2213-2600(22)00049-2. Epub 2022 Apr 12. Lancet Respir Med. 2022. PMID: 35427529 No abstract available.
-
COPD, smoking, and social justice.Lancet Respir Med. 2022 May;10(5):428-430. doi: 10.1016/S2213-2600(22)00130-8. Epub 2022 Apr 12. Lancet Respir Med. 2022. PMID: 35427531 No abstract available.
References
-
- Barnes PJ. Endo-phenotyping of COPD patients. Expert Rev Respir Med 2021; 15: 27–37. - PubMed
-
- Agustí A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med 2019; 381: 1248–56. - PubMed
-
- Hunter DJ. Gene–environment interactions in human diseases. Nat Rev Genet 2005; 6: 287–98. - PubMed
